In a nutshell This study determined long-term risk of death from all causes using data from 1,541 early-stage (stage 1-2) Hodgkin’s lymphoma (HL) patients who received radiotherapy (RT) alone or RT with chemotherapy. This study concluded that this risk was significantly lower for patients treated in the most recent era of radiation therapy thanks...
Read More
In a nutshell This paper is a review of the effectiveness of chemotherapy alone or chemotherapy plus radiotherapy for treating adult patients with early stage Hodgkin lymphoma. The review concluded that, for the same chemotherapy regimen, RT may increase progression free survival, but has little effect on overall survival for patients. Some background...
Read MoreIn a nutshell This phase 2 clinical trial will test the effectiveness of TGR-1202 in patients with relapsed or refractory follicular lymphoma. The primary outcome will be measured by the overall response rate. This trial is being conducted at the Columbia University Medical Center in New York, New York. The details TGR-1202 (umbralisib)...
Read MoreIn a nutshell This study provided a long-term follow-up of patients diagnosed with early-stage Hodgkin lymphoma. The study concluded that current strategies for reduced intensity treatment of early-stage Hodgkin lymphoma are generally safe and effective. Some background Hodgkin lymphoma (HL) is generally considered a curable disease....
Read More
In a nutshell This trial compared the outcomes of ABVD and Stanford-V chemotherapy in patients with stage I or stage II bulky Hodgkin lymphoma. The authors concluded that both treatments were equally effective. Some background Hodgkin Lymphoma is a cancer of the lymph system. Patients with bulky disease have tumors larger than 10 cm....
Read More
In a nutshell The current study examined the use of involved node radiation therapy with different delivery techniques in patients with early-stage Hodgkin lymphoma. The study suggests that radiation to a smaller area is safe and effective in these patients. Some background The main treatment options for Hodgkin lymphoma are chemotherapy combined...
Read More
In a nutshell This study reviewed the treatment options for early-stage Hodgkin lymphoma. Some background Early-stage Hodgkin lymphoma refers to stages I and II. Early-stage can be further divided into favorable or unfavorable. Patients with unfavorable disease may present with certain risk factors. These include large chest tumors, inflammation...
Read MoreIn a nutshell This study aimed to determine whether chemotherapy and radiation doses can be reduced in early-stage favorable Hodgkin lymphoma treatment. This study concluded that fewer chemotherapy cycles and a lower dose of radiation was effective in patients with a good prognosis. Some background Radiation was the original standard...
Read More
In a nutshell The current study examined the safety and effectiveness of the chemotherapy combination ABVD in early-stage Hodgkin lymphoma patients over the age of 60. This study concluded that the standard four cycles of ABVD led to increased need for dose reduction and increased negative effects in older patients. Some background While the...
Read More
In a nutshell This study examined the safety and effectiveness of the Stanford V chemotherapy combination in patients with early-stage Hodgkin lymphoma. The authors concluded that Stanford V was effective in the long-term in these patients. Some background Early-stage Hodgkin lymphoma (stages I-II) is considered to be a curable disease. Treatment...
Read More
In a nutshell This study examined the safety and effectiveness of BEACOPP chemotherapy combined with ABVD chemotherapy in patients with early unfavorable Hodgkin lymphoma. This study concluded that the combination of the two chemotherapies was more effective than ABVD alone. The combination increased the rate of negative side effects. Some background...
Read More
